Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement (NASDAQ:ARDX)

[ad_1]

bubble and molecule

tiratus phaesuwan/iStock via Getty Images

The last time I spoke about Ardelyx, Inc. (NASDAQ:ARDX) in the Seeking Alpha article entitled “Ardelyx: Underappreciated Biotech With Potential FDA Approval On Deck,” it was gearing up to

[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *